Medtronic plc (NYSE:MDT) Stock Position Cut by Rothschild Capital Partners LLC

by · The Cerbat Gem

Rothschild Capital Partners LLC trimmed its stake in shares of Medtronic plc (NYSE:MDT – Free Report) by 90.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 3,786 shares of the medical technology company’s stock after selling 33,933 shares during the period. Rothschild Capital Partners LLC’s holdings in Medtronic were worth $302,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in MDT. Mainstream Capital Management LLC bought a new stake in Medtronic in the fourth quarter worth about $26,000. Stephens Consulting LLC grew its stake in shares of Medtronic by 145.7% in the 4th quarter. Stephens Consulting LLC now owns 344 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 204 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Medtronic by 753.8% in the 4th quarter. Rakuten Securities Inc. now owns 333 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 294 shares in the last quarter. Fiduciary Advisors Inc. acquired a new stake in Medtronic during the fourth quarter valued at approximately $36,000. Finally, Kieckhefer Group LLC acquired a new position in Medtronic in the fourth quarter worth approximately $40,000. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Trading Up 0.6 %

Shares of NYSE:MDT opened at $84.24 on Friday. Medtronic plc has a 12-month low of $75.96 and a 12-month high of $96.25. The company has a quick ratio of 1.39, a current ratio of 1.90 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $108.04 billion, a P/E ratio of 25.60, a price-to-earnings-growth ratio of 2.22 and a beta of 0.79. The firm has a fifty day moving average of $88.18 and a two-hundred day moving average of $87.29.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.36 by $0.03. Medtronic had a return on equity of 14.07% and a net margin of 12.83%. The firm had revenue of $8.29 billion during the quarter, compared to analysts’ expectations of $8.33 billion. On average, equities analysts expect that Medtronic plc will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 11th. Investors of record on Friday, March 28th were given a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 3.32%. The ex-dividend date was Friday, March 28th. Medtronic’s payout ratio is presently 85.11%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Medtronic in a research note on Wednesday, February 19th. Robert W. Baird increased their price target on Medtronic from $90.00 to $91.00 and gave the company a “neutral” rating in a research report on Wednesday, February 19th. UBS Group boosted their price objective on Medtronic from $85.00 to $95.00 and gave the stock a “neutral” rating in a report on Wednesday, February 19th. Citigroup upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and raised their target price for the stock from $92.00 to $107.00 in a report on Tuesday, March 4th. Finally, Truist Financial cut their price target on shares of Medtronic from $93.00 to $90.00 and set a “hold” rating on the stock in a report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $96.14.

View Our Latest Stock Report on MDT

Medtronic Profile

(Free Report)

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.

Recommended Stories

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).